Immunovant (IMVT) News Today $15.49 -0.17 (-1.09%) Closing price 04:00 PM EasternExtended Trading$15.58 +0.08 (+0.55%) As of 06:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMVT Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Immunovant: Navigating The Complexities Of The FcRn Landscape (Downgrade)June 13 at 2:06 PM | seekingalpha.comImmunovant, Inc. (NASDAQ:IMVT) Receives Consensus Rating of "Moderate Buy" from BrokeragesImmunovant, Inc. (NASDAQ:IMVT - Get Free Report) has earned an average recommendation of "Moderate Buy" from the ten analysts that are currently covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and onJune 12, 2025 | marketbeat.comCantor Fitzgerald Forecasts Immunovant FY2027 EarningsJune 12, 2025 | americanbankingnews.comBrokers Set Expectations for Immunovant FY2027 EarningsImmunovant, Inc. (NASDAQ:IMVT - Free Report) - Analysts at Cantor Fitzgerald issued their FY2027 earnings estimates for shares of Immunovant in a research note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst P. Agrawal forecasts that the company will post earnings of ($3.26) peJune 10, 2025 | marketbeat.comImmunovant (NASDAQ:IMVT) Stock Price Down 4.7% - Here's WhyImmunovant (NASDAQ:IMVT) Shares Down 4.7% - Here's WhyJune 9, 2025 | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $6.92 Million Stock Position in Immunovant, Inc. (NASDAQ:IMVT)UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lowered its holdings in shares of Immunovant, Inc. (NASDAQ:IMVT - Free Report) by 10.2% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 279,252 shares oJune 2, 2025 | marketbeat.comHC Wainwright Estimates Immunovant FY2030 EarningsImmunovant, Inc. (NASDAQ:IMVT - Free Report) - Research analysts at HC Wainwright issued their FY2030 EPS estimates for shares of Immunovant in a report released on Friday, May 30th. HC Wainwright analyst D. Tsao expects that the company will post earnings per share of $1.77 for the year. HC WainJune 2, 2025 | marketbeat.comLeerink Partnrs Estimates Immunovant FY2030 EarningsImmunovant, Inc. (NASDAQ:IMVT - Free Report) - Leerink Partnrs issued their FY2030 earnings per share (EPS) estimates for shares of Immunovant in a report released on Thursday, May 29th. Leerink Partnrs analyst T. Smith anticipates that the company will post earnings per share of $1.06 for the yeJune 2, 2025 | marketbeat.comImmunovant (NASDAQ:IMVT) Shares Gap Up on Earnings BeatImmunovant (NASDAQ:IMVT) Shares Gap Up After Strong EarningsMay 30, 2025 | marketbeat.comImmunovant (NASDAQ:IMVT) Posts Earnings Results, Beats Expectations By $0.08 EPSImmunovant (NASDAQ:IMVT - Get Free Report) issued its quarterly earnings data on Thursday. The company reported ($0.64) EPS for the quarter, topping the consensus estimate of ($0.72) by $0.08. During the same quarter in the previous year, the business earned ($0.52) earnings per share.May 30, 2025 | marketbeat.comImmunovant, Inc. Reports Strategic Progress and Financial ResultsMay 30, 2025 | tipranks.comImmunovant Stock Rises On Narrower-Than-Expected Q1 Loss: Retail’s Still On The FenceMay 29, 2025 | msn.comImmunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025May 29, 2025 | globenewswire.comImmunovant (IMVT) to Release Earnings on WednesdayImmunovant (NASDAQ:IMVT) will be releasing its Q4 2025 earnings before the market opens on Wednesday, June 4. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-6-4-immunovant-inc-stock/)May 29, 2025 | marketbeat.comH.C. Wainwright Keeps Buy Rating on Roivant Sciences (ROIV) StockMay 28, 2025 | msn.comNuveen Asset Management LLC Sells 189,759 Shares of Immunovant, Inc. (NASDAQ:IMVT)Nuveen Asset Management LLC lessened its holdings in Immunovant, Inc. (NASDAQ:IMVT - Free Report) by 17.2% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 915,151 shares of the company's stock after selling 189,759 shares durMay 26, 2025 | marketbeat.comBank of America Corp DE Buys 114,511 Shares of Immunovant, Inc. (NASDAQ:IMVT)Bank of America Corp DE raised its stake in shares of Immunovant, Inc. (NASDAQ:IMVT - Free Report) by 50.4% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 341,535 shares of the company's stock after purchasing an additional 114,511 shares during the period.May 26, 2025 | marketbeat.comWoodline Partners LP Sells 772,251 Shares of Immunovant, Inc. (NASDAQ:IMVT)Woodline Partners LP trimmed its stake in shares of Immunovant, Inc. (NASDAQ:IMVT - Free Report) by 54.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 642,726 shares of the company's stock afterMay 24, 2025 | marketbeat.comImmunovant, Inc. (NASDAQ:IMVT) Shares Purchased by Two Seas Capital LPTwo Seas Capital LP raised its position in shares of Immunovant, Inc. (NASDAQ:IMVT - Free Report) by 123.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,511,614 shares of the company's stock after acquiMay 23, 2025 | marketbeat.comRafferty Asset Management LLC Trims Stock Holdings in Immunovant, Inc. (NASDAQ:IMVT)Rafferty Asset Management LLC reduced its stake in Immunovant, Inc. (NASDAQ:IMVT - Free Report) by 23.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 116,624 shares of the company's stock afterMay 22, 2025 | marketbeat.comIMVT INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Announces Investigation into a Private Placement Transaction by Immunovant, Inc. and Encourages Investors to Contact the FirmMay 21, 2025 | businesswire.comVestal Point Capital LP Makes New Investment in Immunovant, Inc. (NASDAQ:IMVT)Vestal Point Capital LP acquired a new position in Immunovant, Inc. (NASDAQ:IMVT - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 45,000 shares of the company's stock, valued at approximatMay 21, 2025 | marketbeat.comTyro Capital Management LLC Has $3.75 Million Stock Holdings in Immunovant, Inc. (NASDAQ:IMVT)Tyro Capital Management LLC cut its holdings in Immunovant, Inc. (NASDAQ:IMVT - Free Report) by 39.9% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 151,456 shares of the company's stock after selling 100,693 shares during the quarter. Immunovant comprisesMay 20, 2025 | marketbeat.comImmunovant, Inc. (NASDAQ:IMVT) Given Average Rating of "Moderate Buy" by AnalystsImmunovant, Inc. (NASDAQ:IMVT - Get Free Report) has been assigned an average rating of "Moderate Buy" from the ten ratings firms that are presently covering the stock, MarketBeat.com reports. Two analysts have rated the stock with a hold recommendation, seven have issued a buy recommendation andMay 20, 2025 | marketbeat.comEnsign Peak Advisors Inc Cuts Position in Immunovant, Inc. (NASDAQ:IMVT)Ensign Peak Advisors Inc trimmed its stake in shares of Immunovant, Inc. (NASDAQ:IMVT - Free Report) by 87.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 19,706 shares of the company's stock after sellingMay 19, 2025 | marketbeat.comBNP Paribas Financial Markets Takes Position in Immunovant, Inc. (NASDAQ:IMVT)BNP Paribas Financial Markets acquired a new stake in Immunovant, Inc. (NASDAQ:IMVT - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 85,201 shares of the company's stock, valueMay 19, 2025 | marketbeat.comRTW Investments LP Purchases New Shares in Immunovant, Inc. (NASDAQ:IMVT)RTW Investments LP purchased a new stake in Immunovant, Inc. (NASDAQ:IMVT - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 530,614 shares of the company's stock, valued at approximatelMay 18, 2025 | marketbeat.comImmunovant, Inc. (NASDAQ:IMVT) Shares Bought by Northern Trust CorpNorthern Trust Corp raised its holdings in Immunovant, Inc. (NASDAQ:IMVT - Free Report) by 4.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 527,367 shares of the company's stock after purchasing an aMay 18, 2025 | marketbeat.comProsight Management LP Sells 64,477 Shares of Immunovant, Inc. (NASDAQ:IMVT)Prosight Management LP trimmed its position in Immunovant, Inc. (NASDAQ:IMVT - Free Report) by 17.4% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 305,523 shares of the company's stock after selling 64,477 shares during the period. Immunovant accounts for aMay 17, 2025 | marketbeat.comOccudo Quantitative Strategies LP Makes New Investment in Immunovant, Inc. (NASDAQ:IMVT)Occudo Quantitative Strategies LP acquired a new stake in Immunovant, Inc. (NASDAQ:IMVT - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 34,731 shares of the company's stock, valued at approMay 16, 2025 | marketbeat.comIs Immunovant, Inc. (IMVT) The Most Undervalued Stock With Smart Money Ratings?May 15, 2025 | msn.comOrbimed Advisors LLC Buys New Holdings in Immunovant, Inc. (NASDAQ:IMVT)Orbimed Advisors LLC purchased a new position in Immunovant, Inc. (NASDAQ:IMVT - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 78,500 shares of the company's stock, valMay 15, 2025 | marketbeat.com34,337 Shares in Immunovant, Inc. (NASDAQ:IMVT) Bought by J. Goldman & Co LPJ. Goldman & Co LP bought a new stake in Immunovant, Inc. (NASDAQ:IMVT - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 34,337 shares of the company's stock, valued atMay 14, 2025 | marketbeat.comGranahan Investment Management LLC Makes New Investment in Immunovant, Inc. (NASDAQ:IMVT)Granahan Investment Management LLC acquired a new stake in Immunovant, Inc. (NASDAQ:IMVT - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 149,396 shares of the company's stock, valued at approximately $3,701,000. GranaMay 13, 2025 | marketbeat.comDimensional Fund Advisors LP Sells 58,463 Shares of Immunovant, Inc. (NASDAQ:IMVT)Dimensional Fund Advisors LP decreased its holdings in shares of Immunovant, Inc. (NASDAQ:IMVT - Free Report) by 12.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 403,747 shares of the compMay 12, 2025 | marketbeat.comRaymond James Financial Inc. Buys Shares of 20,382 Immunovant, Inc. (NASDAQ:IMVT)Raymond James Financial Inc. acquired a new position in shares of Immunovant, Inc. (NASDAQ:IMVT - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor acquired 20,382 shares of the company's stock, valued at approximately $505,000. OtherMay 11, 2025 | marketbeat.comDAFNA Capital Management LLC Purchases 56,000 Shares of Immunovant, Inc. (NASDAQ:IMVT)DAFNA Capital Management LLC grew its position in shares of Immunovant, Inc. (NASDAQ:IMVT - Free Report) by 107.7% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 107,996 shares of the companMay 10, 2025 | marketbeat.comDeep Track Capital LP Has $148.62 Million Position in Immunovant, Inc. (NASDAQ:IMVT)Deep Track Capital LP lifted its holdings in Immunovant, Inc. (NASDAQ:IMVT - Free Report) by 38.0% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 6,000,000 shares of the company's stock after buying an additional 1,652,536 shares during thMay 9, 2025 | marketbeat.comHsbc Holdings PLC Invests $780,000 in Immunovant, Inc. (NASDAQ:IMVT)Hsbc Holdings PLC purchased a new stake in Immunovant, Inc. (NASDAQ:IMVT - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 31,896 shares of the company's stock, valued at approximately $780,000. A number of otherMay 7, 2025 | marketbeat.comImmunovant, Inc. (NASDAQ:IMVT) Shares Acquired by Baker BROS. Advisors LPBaker BROS. Advisors LP boosted its stake in Immunovant, Inc. (NASDAQ:IMVT - Free Report) by 39.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,707,881 shares of the company's stock after acquiring an aMay 6, 2025 | marketbeat.comBoxer Capital Management LLC Makes New $20.44 Million Investment in Immunovant, Inc. (NASDAQ:IMVT)Boxer Capital Management LLC bought a new position in Immunovant, Inc. (NASDAQ:IMVT - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 825,000 shares of the company's stock, valued at approximately $20,435,000. IMay 4, 2025 | marketbeat.comImmunovant, Inc. (NASDAQ:IMVT) Shares Sold by Price T Rowe Associates Inc. MDPrice T Rowe Associates Inc. MD reduced its position in shares of Immunovant, Inc. (NASDAQ:IMVT - Free Report) by 24.2% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 916,250 shares of the company's stockMay 4, 2025 | marketbeat.comAquatic Capital Management LLC Takes Position in Immunovant, Inc. (NASDAQ:IMVT)Aquatic Capital Management LLC acquired a new position in shares of Immunovant, Inc. (NASDAQ:IMVT - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 47,648 shares of the company's stock, valueMay 2, 2025 | marketbeat.comEmerald Mutual Fund Advisers Trust Decreases Stock Holdings in Immunovant, Inc. (NASDAQ:IMVT)Emerald Mutual Fund Advisers Trust lowered its position in Immunovant, Inc. (NASDAQ:IMVT - Free Report) by 15.0% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 156,097 shares of the company's stock after seMay 1, 2025 | marketbeat.comThyroid Eye Disease Treatment Market Size (7MM) was ~USD 1,993 Million in 2022 and is projected to increase by 2034, estimates DelveInsightApril 30, 2025 | theglobeandmail.comImmunovant (NASDAQ:IMVT) Shares Up 3.4% - Time to Buy?Immunovant (NASDAQ:IMVT) Stock Price Up 3.4% - What's Next?April 30, 2025 | marketbeat.comRenaissance Technologies LLC Sells 108,100 Shares of Immunovant, Inc. (NASDAQ:IMVT)Renaissance Technologies LLC lessened its stake in shares of Immunovant, Inc. (NASDAQ:IMVT - Free Report) by 57.2% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 80,900 shares of the company's stock after selling 108,100 shares during the period. RenaissancApril 28, 2025 | marketbeat.comImmunovant, Inc. (NASDAQ:IMVT) Shares Bought by Two Seas Capital LPTwo Seas Capital LP grew its stake in Immunovant, Inc. (NASDAQ:IMVT - Free Report) by 123.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,511,614 shares of the company's stock after purchasing an additApril 27, 2025 | marketbeat.comT. Rowe Price Investment Management Inc. Increases Stock Position in Immunovant, Inc. (NASDAQ:IMVT)T. Rowe Price Investment Management Inc. lifted its stake in Immunovant, Inc. (NASDAQ:IMVT - Free Report) by 53.6% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 5,117,234 shares of the company's stock after acquiring an additional 1,786,217April 27, 2025 | marketbeat.comImmunovant, Inc. (NASDAQ:IMVT) CTO Jay S. Stout Sells 1,925 SharesApril 26, 2025 | insidertrades.com Get Immunovant News Delivered to You Automatically Sign up to receive the latest news and ratings for IMVT and its competitors with MarketBeat's FREE daily newsletter. Email Address IMVT Media Mentions By Week IMVT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IMVT News Sentiment▼0.990.90▲Average Medical News Sentiment IMVT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IMVT Articles This Week▼86▲IMVT Articles Average Week Get Immunovant News Delivered to You Automatically Sign up to receive the latest news and ratings for IMVT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MRNA News Today ASND News Today VTRS News Today QGEN News Today BPMC News Today ROIV News Today RVMD News Today BBIO News Today ELAN News Today VRNA News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IMVT) was last updated on 6/16/2025 by MarketBeat.com Staff From Our Partners[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredSomething Big Is Coming...Man who predicted Lehman Crash Warns "Get OUT of Cash" He predicted the 2008 crisis and recommended shortin...Stansberry Research | SponsoredBREAKING: Trump vs. Elon Feud Threatens Your Retirement – Protect Yourself NOW"This isn't just a war of words. This is a financial time bomb. The escalating battle between Donald Trump a...American Alternative | SponsoredThe mainstream media is wrong about AI — againThe mainstream media got it wrong … yet again. Chinese AI chatbot DeepSeek turned the tech world on its hea...Weiss Ratings | SponsoredWarning: Prepare to Be Shocked by These PayoutsThere's a strategy out there paying up to 70% on tech stocks like Amazon, Tesla, and Microsoft—stocks that don...Investors Alley | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunovant, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunovant With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
